LOS ANGELES, CA / ACCESSWIRE / July 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK, NY / ACCESSWIRE / July 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.
NEW YORK, NY / ACCESSWIRE / July 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.
NEW YORK CITY, NY / ACCESSWIRE / July 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX). Investors who purchased HilleVax securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HLVX.
NEW YORK, NY / ACCESSWIRE / July 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.
LOS ANGELES, CA / ACCESSWIRE / July 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK, NY / ACCESSWIRE / July 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.
NEW YORK CITY, NY / ACCESSWIRE / July 18, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX). Investors who purchased HilleVax securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HLVX.
NEW YORK, NY / ACCESSWIRE / July 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.
LOS ANGELES, CA / ACCESSWIRE / July 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
NEW YORK, NY / ACCESSWIRE / July 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of HilleVax, Inc. ("HilleVax") (NASDAQ:HLVX) concerning possible violations of federal securities laws. On July 8, 2024, HilleVax was the subject of a Fierce Biotech article.
NEW YORK CITY, NY / ACCESSWIRE / July 17, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of HilleVax, Inc. ("HilleVax" or "the Company") (NASDAQ:HLVX). Investors who purchased HilleVax securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/HLVX.